利用质量登记系统创新性开展胸主动脉腔内修复治疗主动脉夹层的上市后器械评价
本文介绍VQI注册数据库用于FDA上市后器械评价的创新项目。该项目纳入急性和慢性B型主动脉夹层TEVAR患者,分5年随访组(急性、慢性各200例)和1年随访组(急性、慢性各100例),结果显示入组迅速、数据完整性好,两种FDA批准的夹层器械代表均衡,支持该模式用于上市后器械评估。
要点
- VQI注册系统可在24个月内完成5年随访组各200例入组。
- 该模式与常规临床实践和质量改进结合,医生额外负担小。
- 数据完整性和随访良好,两种FDA批准夹层器械代表均衡。
核心结论
- 尽管长期随访完整性待确定,但数据收集速度支持该结构用于上市后器械评价。
研究设计与样本
- 利用VQI国家网络注册,连续纳入接受TEVAR的B型主动脉夹层患者,分5年随访组(急性200例、慢性200例)和1年随访组(急性100例、慢性100例)。
主要发现
- 5年随访组急性和慢性夹层各200例在项目启动≤24个月内完成入组,1年随访组数据收集接近完成。
- 数据完整性和随访优秀,两种FDA批准的夹层器械代表均衡。
临床怎么用
- 该模式与常规临床实践和质量改进结合,医生额外负担小,便于患者入组。
局限性
- 长期随访完整性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: United States Food and Drug Administration (FDA)-mandated postapproval studies have long been a mainstay of the continued evaluation of high-risk medical devices after initial marketing approval; however, these studies often present challenges related to patient/physician recruitment and retention. Retrospective single-center studies also do not fully represent the spectrum of real-world performance nor are they likely to have a sufficiently large enough sample size to detect important signals. In recent years, The FDA Center for Devices and Radiological Health has been promoting the development and use of patient registries to advance infrastructure and methodologies for medical device investigation. The FDA 2012 document, "Strengthening the National System for Medical Device Post-market Surveillance," highlighted registries as a core foundational infrastructure when linked to other complementary data sources, including embedded unique device identification. The Vascular Quality Initiative (VQI) thoracic endovascular aortic repair for type B aortic dissection project is an innovative method of using quality improvement registries to meet the needs of device evaluation after market approval. Here we report the organization and background of this project and highlight the innovation facilitated by collaboration of physicians, the FDA, and device manufacturers. METHODS: This effort used an existing national network of VQI participants to capture patients undergoing thoracic endovascular aortic repair for acute type B aortic dissection within a registry that aligns with standard practice and existing quality efforts. The VQI captures detailed patient, device, and procedural data for consecutive eligible cases under the auspices of a Patient Safety Organization (PSO). Patients were divided into a 5-year follow-up group (200 acute; 200 chronic dissections) and a 1-year follow-up group (100 acute; 100 chronic). The 5-year cohort required additional imaging details, and the 1-year group required standard VQI registry data entry. RESULTS: The sample size of patients in each of the 5-year acute and chronic dissection arms was achieved ≤24 months of project initiation, and data capture for the 1-year follow-up group is also nearly complete. Data completeness and follow-up has been excellent, and the two FDA-approved devices for dissection are equally represented. CONCLUSIONS: Although the completeness of long-term follow-up is yet to be determined, the rapidity of data collection supports the use of this construct for device assessment after market approval. The alignment of this effort with routine clinical practice and ongoing quality improvement initiatives is critical and has required minimal additional effort by practitioners, thus facilitating patient inclusion. Importantly, the success and development of this unique project has helped inform FDA strategy for future device evaluation after market approval.
引用
- Beck AW, Lombardi JV, Abel DB, et al. Innovative postmarket device evaluation using a quality registry to monitor thoracic endovascular aortic repair in the treatment of aortic dissection. J Vasc Surg. 2017. PMID: 28216355. doi:10.1016/j.jvs.2016.11.054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。